Payment overview · 2025
General Payments
$996.46
65 reported records · 19 companies
Healthcare provider profile · identity verified
Gregg A Pearson, DO
Allopathic & Osteopathic Physicians|Family Medicine · WATERFORD, NJ · NPI 1083645972
Verified facts
What the public records show
CMS Open Payments records show Gregg A Pearson, DO received $996.46 in general payments during 2025 across 65 reported records.
ABBVIE INC. accounted for 22.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Trelegy Ellipta, Vraylar, Xyosted.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Vraylar by this doctor in 2024.
Antares Pharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XYOSTED as an associated drug or biological on 18015 records involving 7619 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Xyosted by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 185 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $220.96 | 22.2% | 18 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $163.07 | 16.4% | 8 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $112.86 | 11.3% | 6 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $93.88 | 9.4% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $81.35 | 8.2% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $50.64 | 5.1% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $47.34 | 4.8% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.32 | 2.8% | 4 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $28.28 | 2.8% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $27.63 | 2.8% | 2 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $18.44 | 1.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.69 | 1.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.05 | 1.6% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.94 | 1.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.82 | 1.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.73 | 1.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.98 | 1.5% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $14.28 | 1.4% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.20 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $976.24 | 64 |
| Education | $20.22 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $189.15 | 16 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $119.87 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $112.86 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $93.88 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $64.03 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $63.85 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $57.24 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $43.87 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $43.20 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $34.15 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $34.15 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $34.15 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $28.32 | 4 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $28.28 | 2 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $27.63 | 2 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $18.57 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $18.44 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $17.50 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.05 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.94 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $14.28 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.20 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $13.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 185 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 165 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 118 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 64 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 91 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XYOSTED xyosted |
2025 | Xyosted | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
81 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
99 | 24 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Antares Pharma, Inc. Exact reporting entity; no affiliate inference |
2025 | XYOSTED open payments reported associated product |
CMS Open Payments — General Payments 18015 supporting records · 7619 recipient NPIs · example record 1235880452 |
Xyosted · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
165 | 33 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
118 | 31 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
91 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
118 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
64 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
185 | 41 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
29 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1378 | 319 |
| Levothyroxine Sodium | Levothyroxine Sodium | 915 | 180 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 852 | 228 |
| Lisinopril | Lisinopril | 747 | 181 |
| Metoprolol Succinate | Metoprolol Succinate | 713 | 160 |
| Atorvastatin Calcium | Atorvastatin Calcium | 708 | 195 |
| Furosemide | Furosemide | 636 | 168 |
| Metformin Hcl | Metformin Hcl | 632 | 164 |
| Pantoprazole Sodium | Pantoprazole Sodium | 612 | 157 |
| Losartan Potassium | Losartan Potassium | 597 | 145 |
| Fluticasone Propionate | Fluticasone Propionate | 471 | 206 |
| Omeprazole | Omeprazole | 385 | 94 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 328 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 317 | 83 |
| Alprazolam | Alprazolam | 306 | 52 |
| Oxycodone Hcl | Oxycodone Hcl | 302 | 36 |
| Methylprednisolone | Methylprednisolone | 287 | 194 |
| Montelukast Sodium | Montelukast Sodium | 284 | 60 |
| Gabapentin | Gabapentin | 283 | 69 |
| Glipizide Er | Glipizide | 283 | 76 |
| Tramadol Hcl | Tramadol Hcl | 282 | 65 |
| Fenofibrate | Fenofibrate | 272 | 82 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 269 | 75 |
| Hydralazine Hcl | Hydralazine Hcl | 259 | 59 |
| Sertraline Hcl | Sertraline Hcl | 257 | 60 |
| Simvastatin | Simvastatin | 257 | 63 |
| Potassium Chloride | Potassium Chloride | 255 | 77 |
| Pravastatin Sodium | Pravastatin Sodium | 254 | 54 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 243 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 220 | 65 |
| Zolpidem Tartrate | Zolpidem Tartrate | 219 | 41 |
| Ozempic | Semaglutide | 207 | 39 |
| Meloxicam | Meloxicam | 198 | 77 |
| Clopidogrel | Clopidogrel Bisulfate | 197 | 52 |
| Eliquis | Apixaban | 185 | 41 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 183 | 34 |
| Ibuprofen | Ibuprofen | 178 | 46 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 175 | 74 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 171 | 40 |
| Farxiga | Dapagliflozin Propanediol | 165 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 164 | 47 |
| Azithromycin | Azithromycin | 159 | 120 |
| Temazepam | Temazepam | 157 | 37 |
| Diazepam | Diazepam | 152 | 30 |
| Famotidine | Famotidine | 152 | 40 |
| Bupropion Xl | Bupropion Hcl | 137 | 30 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 135 | 94 |
| Escitalopram Oxalate | Escitalopram Oxalate | 133 | 40 |
| Citalopram Hbr | Citalopram Hydrobromide | 126 | 31 |
| Atenolol | Atenolol | 125 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 122 | 33 |
| Donepezil Hcl | Donepezil Hcl | 119 | 25 |
| Jardiance | Empagliflozin | 118 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 107 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 103 | 79 |
| Lorazepam | Lorazepam | 103 | 22 |
| Levofloxacin | Levofloxacin | 102 | 79 |
| Allopurinol | Allopurinol | 100 | 29 |
| Synthroid | Levothyroxine Sodium | 99 | 24 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 98 | 23 |
| Carvedilol | Carvedilol | 98 | 32 |
| Clonazepam | Clonazepam | 94 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 93 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 91 | 21 |
| Alendronate Sodium | Alendronate Sodium | 90 | 20 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 90 | 54 |
| Aripiprazole | Aripiprazole | 89 | 16 |
| Repatha Sureclick | Evolocumab | 87 | 14 |
| Klor-Con M20 | Potassium Chloride | 86 | 33 |
| Meclizine Hcl | Meclizine Hcl | 86 | 45 |
| Creon | Lipase/Protease/Amylase | 81 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 81 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 81 | 61 |
| Duloxetine Hcl | Duloxetine Hcl | 79 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 77 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 75 | 23 |
| Pregabalin | Pregabalin | 71 | 17 |
| Ezetimibe | Ezetimibe | 70 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 69 | 21 |
| Memantine Hcl | Memantine Hcl | 69 | 14 |
| Oxycontin | Oxycodone Hcl | 68 | suppressed |
| Mounjaro | Tirzepatide | 64 | suppressed |
| Ramipril | Ramipril | 64 | 12 |
| Prednisone | Prednisone | 63 | 37 |
| Xarelto | Rivaroxaban | 63 | 13 |
| Trazodone Hcl | Trazodone Hcl | 62 | 12 |
| Amoxicillin | Amoxicillin | 59 | 48 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 59 | 44 |
| Clonidine Hcl | Clonidine Hcl | 59 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 59 | 28 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 57 | 16 |
| Warfarin Sodium | Warfarin Sodium | 57 | 12 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 56 | 42 |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 55 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 53 | 18 |
| Azelastine Hcl | Azelastine Hcl | 52 | 24 |
| Valacyclovir | Valacyclovir Hcl | 52 | 24 |
| Metformin Hcl Er | Metformin Hcl | 51 | 14 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 50 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 50 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 16 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 49 | 43 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 48 | suppressed |
| Celecoxib | Celecoxib | 46 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 45 | 17 |
| Novolog Flexpen | Insulin Aspart | 45 | 13 |
| Hydrocortisone | Hydrocortisone | 44 | suppressed |
| Risperidone | Risperidone | 44 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 43 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 43 | suppressed |
| Finasteride | Finasteride | 43 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 43 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 42 | suppressed |
| Spironolactone | Spironolactone | 42 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 41 | 13 |
| Lidocaine | Lidocaine | 41 | 18 |
| Fenofibric Acid | Fenofibric Acid (Choline) | 40 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 40 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 39 | suppressed |
| Entresto | Sacubitril/Valsartan | 38 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 37 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 37 | suppressed |
| Glimepiride | Glimepiride | 36 | suppressed |
| Vraylar | Cariprazine Hcl | 36 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 35 | suppressed |
| Naproxen | Naproxen | 35 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 35 | suppressed |
| Baclofen | Baclofen | 34 | suppressed |
| Ondansetron Odt | Ondansetron | 34 | 11 |
| Lansoprazole | Lansoprazole | 31 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 31 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 30 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 29 | suppressed |
| Glipizide | Glipizide | 29 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 29 | 28 |
| Testosterone | Testosterone | 29 | suppressed |
| Xyosted | Testosterone Enanthate | 29 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 28 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 28 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 27 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Fluconazole | Fluconazole | 26 | 16 |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 23 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 23 | 13 |
| Topiramate | Topiramate | 23 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 22 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Repaglinide | Repaglinide | 21 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Metolazone | Metolazone | 19 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 18 | suppressed |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 18 | suppressed |
| Verapamil Sr | Verapamil Hcl | 18 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 17 | suppressed |
| Belbuca | Buprenorphine Hcl | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Permethrin | Permethrin | 17 | 12 |
| Tiadylt Er | Diltiazem Hcl | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Pentoxifylline | Pentoxifylline | 15 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Anastrozole | Anastrozole | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Humalog | Insulin Lispro | 14 | suppressed |
| Indomethacin | Indomethacin | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Mesalamine Er | Mesalamine | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 13 | suppressed |
| Lumigan | Bimatoprost | 13 | suppressed |
| Mesalamine Dr | Mesalamine | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $996.46 · 65 records | ABBVIE INC. | ABRYSVO, ACCRUFER, AIRSUPRA, AREXVY, BOTOX, BREZTRI, CAPLYTA, COMIRNATY, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, JATENZO, KISUNLA, Kerendia, MOUNJARO, NEXLETOL, NURTEC ODT, PREVNAR 20, QULIPTA, REXULTI, TRELEGY ELLIPTA, VOQUEZNA, VRAYLAR, XIFAXAN, XYOSTED, ZENPEP, ZEPBOUND, ZORYVE | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error